Company intelligence / Profile preview
Healios
Chiyoda-ku, Tokyo, Japanhealios.co.jp ↗
- Ownership
- Private
- Employees
- ~60
- Development stage
- Commercial
01
Overview
Healios has advanced its lead asset, HLCM051, into late-stage clinical trials for ARDS and ischemic stroke. The company is also developing iPSC-derived natural killer cells for cancer immunotherapy and retinal therapies. It has demonstrated the ability to manufacture at scale using proprietary technologies and maintains a robust R&D pipeline with several assets in various stages of development[4][5].
- Therapeutic areas
- PulmonologyCardiovascularOphthalmologyOtherOncology
- Modalities
- Induced pluripotent stem cell derived therapyCell therapySomatic stem cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Sumitomo Pharma Co., Ltd. (joint venture Sighregen Co., Ltd.)Athersys Inc. (technology acquisition)
Beyond the preview
Go deeper on Healios.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Healios.